Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Schlumberger NV — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.81B), while Schlumberger NV trades at $48.64 (market cap $72.00B). The key difference: Schlumberger NV is far larger — about 25.6× Dyne Therapeutics Inc. Common Stock's market cap, and Schlumberger NV pays a 2.43% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Schlumberger NV for 99 Days on average.
| DYN | SLB | |
|---|---|---|
Market Cap | $2.81B | $72.00B |
Volume | 2,195,902 | 9,844,196 |
Sector | Health | Energy |
52-Week High | $26.78 | $60.10 |
52-Week Low | $14.60 | $32.57 |
Typical Hold Time | 0 Days | 99 Days |
Enterprise Value | $2.13B | $80.72B |
Dividend Yield | — | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
SLB trades at $48.77, showing stable performance with no recent price movement. The stock demonstrates strong fundamental metrics including a 23.79 P/E ratio and 8.53% net income margin, supported by consistent earnings beats in recent quarters. Recent contract wins in Saudi Arabia, Oman, and Mozambique expand the company's international footprint and revenue visibility. Technical indicators show bearish momentum with the price near key support levels at $48.
SLB presents a compelling investment case with strong analyst support (84.85% buy rating) and a $64.58 consensus price target representing 32% upside potential. However, declining profit margins from 12.68% in 2023 to 8.52% projected for 2026 and bearish technical signals warrant caution. The company's expanding contract portfolio provides revenue stability, but investors should monitor margin pressures and oil market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
